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Abstract
We investigated the role of histone deacetylase 4 (HDAC4)
using RNA interference (RNAi) and knockout cells to specif-
ically address its role in cell cycle progression in tumor and
normal cells. Ablation of HDAC4 led to growth inhibition
in human tumor cells but not to detectable effects in normal
human dermal fibroblasts (NHDF) or myelopoietic progeni-
tors. HDAC4/+ or HDAC4/ murine embryonic fibroblasts
showed no detectable growth defects. On the other hand,
HDAC4 RNAi in HeLa cells produced mitotic arrest followed by
caspase-dependent apoptosis. Mitotically arrested cells
showed chromosome segregation defects. Even though the
growth of both p53–wild-type and p53-null tumor cells were
affected by HDAC4 ablation, segregation defects were ob-
served only in p53-null cells. HDAC4 associates with the PP2A-
B56 regulatory subunit, which is known to be involved in
chromosome segregation, and RNAi of either the structural
subunit A or the regulatory subunit B56 of PP2A also caused
chromosome segregation defects. We conclude that HDAC4 is
required for cell cycle progression of tumor cells by multiple
mechanisms, one of which seems to be specific to p53-
deficient cells through chromosome segregation defects. On
the contrary, HDAC4 is not required for the progression of
NHDF. We therefore suggest that systemic selective interfer-
ence with the expression or function of HDAC4 is expected to
have a significant therapeutic window, in particular, for p53-
deficient tumors. [Cancer Res 2009;69(15):6074–82]
Introduction
Histone deacetylases (HDAC) are involved in the control of
histone acetylation status and form a group of 18 proteins divided
into two major families: the zinc-dependent hydrolases, arranged
into class I, II, and IV, and the evolutionarily distinct, NAD-
dependent, sirtuin-like class III proteins (1–3). HDACs are
deregulated or aberrantly expressed in several forms of human
cancer (4), and the HDAC inhibitor vorinostat was recently
approved for the treatment of cutaneous T-cell lymphoma (5).
Vorinostat and other HDAC inhibitors exert their function by
inhibiting several zinc-dependent HDACs. This is in line with the
emerging biology of several HDAC subtypes which suggests that
they play important roles in cancer. For example, each of the
members of the class I enzymes (HDAC1, HDAC2, HDAC3, and
HDAC8) was shown to be functionally involved in tumor growth
and survival, either by aberrant recruitment, expression, or control
of crucial growth and prosurvival pathways in the context of the
transformed phenotype (4–6).
Class IIa HDACs (HDAC4, HDAC5, HDAC7, and HDAC9) are
involved in the control of gene expression through their
recruitment by transcription factors, notably of the Mef and
Runx families, or by transcriptional corepressor complexes such
as CtBP (7–9). They also associate with heterochromatin via
direct binding to HP1 and thus participate in higher-order
structures, possibly contributing to the propagation of repressive
chromatin states (7). Stimulus-dependent nucleocytoplasmic
shuttling emerged as a major control mechanism of the biological
functions of class IIa HDACs. They are targets of several kinases
and some phosphorylated forms are confined to the cytosol by
interaction with 14-3-3 proteins (10, 11). HDAC4 was found to be
frequently mutated in human cancers (12), to associate with
oncoproteins (13), to stabilize hypoxia-inducible factor 1a (14),
and to be a downstream effector of p53-mediated senescence
(15). In tumors, oncogenic Ras (16), DNA damage (17), and
caspase cleavage (18, 19) were also shown to promote nuclear
localization of HDAC4. Once imported, HDAC4 may exert
different nuclear functions that affect differentiation, cell
hypertrophy, and cell cycle progression. In cancer cells, HDAC4
was shown to associate with 53BP1 (20) and to be recruited to
DNA-damage foci, in which it seems to play a pivotal role in foci
resolution. In addition, HDAC4 may localize to and repress G2-M
promoters in a p53-dependent way (17).
In an attempt to define the contributions of individual HDAC
subtypes to tumor proliferation and survival, we performed a small
interfering RNA (siRNA) screen on several human tumor cell lines.
Here, we report that siRNAs directed against HDAC4 turned out to
be particularly effective in inducing cell killing and showed an
excellent window with respect to normal cells. We propose that
HDAC4 has specialized functions in the context of cells with
activated DNA-damage pathways that render these cells particu-
larly sensitive to the loss of HDAC4 expression.
Materials and Methods
Cell culture. HeLa, Saos-2, HCT-116, and A549 cells were from American
Type Culture Collection and were grown according to standard protocols.
Normal human dermal fibroblasts (NHDF; Cambrex) were grown according
to the suggestions of the manufacturer.
Human umbilical cord blood mononuclear cells (Cambrex) were plated
in Iscove’s modified Dulbecco’s medium supplemented with 30% fetal
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bovine serum, 2 mmol/L glutamine, and 1% bovine serum albumin. Murine
embryonic fibroblasts (MEF) were prepared from E13.5 embryos and
cultured in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L of
L-glutamine (Life Technologies), 100 units/mL of penicillin, and 100 Ag/mL
of streptomycin (Life Technologies).
Transfections. Adherent cells at 60% confluency were transfected for
4 h with a final concentration of 50 nmol/L siRNA by using Lipofectamine
2000 (Invitrogen) according to the instructions of the manufacturer.
Cells were trypsinized and re-plated at different concentrations for the
different assays. For cell cycle, HeLa and Saos-2 cells were transfected by
electroporation following the protocols of the manufacturer (Amaxa) using
siRNA at a 10 Amol/L concentration. Myelopoietic progenitors were
electroporated (two pulses at 560 V, 5 ms, square-wave) with 10 Amol/L
siRNAs.
Phenotype rescue. HDAC4-wt inducible clone was plated 12 h before
transfection in the presence or in the absence of 125 ng/mL of doxycycline.
Three millions cells were electroporated with 10 Amol/L siRNAs (Amaxa,
solution V, program O-17) and plated in complete medium with or without
doxycycline.
Cell cycle analysis. Cells and supernatant were collected, centrifuged,
washed, and resuspended in PBS, 0.1% Triton X-100, 40 mmol/L of EDTA,
and 40 Ag/mL of propidium iodide. Cell cycle was monitored using a
FACSCalibur (BD) instrument and analyzed with CellQuest Software. Cell
synchronization was performed by adding thymidine at a 2.5 mmol/L
concentration for 24 h, or nocodazole at a 100 ng/mL concentration for
18 h. Caspase inhibitor Q-VD-OPh (R&D Systems) was used at a 100 Amol/L
final concentration.
RNA extraction and TaqMan. Total RNA was extracted at
24 h posttransfection using the RNeasy kit (Qiagen), according to the
instructions of the manufacturer. Quantitative reverse transcription-PCR
(qRT-PCR) of HDAC4 mRNA was performed in triplicate by using the One-
step RT-PCR Master Mix (Applied Biosystems) with the following set of
primers and probe: primer sense, 5¶-GAGGTTGAGCGTGAGCAAGAT-3¶,
400 nmol/L; primer antisense, 5¶-TAGCGGTGGAGGGACATGTAC-3¶,
400 nmol/L; and probe (FAM-TAMRA), 5¶-TCATCGTGGACTGGGACGTG-
CAC-3¶, 200 nmol/L. Normalization was done on the same amount of
template by amplification of human glyceraldehyde-3-phosphate dehydro-
genase with the corresponding predeveloped TaqMan Assay Reagents
(Applied Biosystems), in triplicate. Detection was performed with an ABI
Prism 7900HT Sequence Detection System.
Immunofluorescence analysis and antibodies. Cells were fixed with
4% paraformaldehyde and permeabilized with 0.1% Triton X-100, then
incubated with primary antibodies followed by secondary antibody (Alexa)
diluted 1:3,000. Coverslips were mounted with ProLong anti-fade (Molecular
Probes) containing 4¶,6-diamidino-2-phenylindole (DAPI). Images were
acquired using a Leica microscope coupled to Metamorph software.
HDAC4 and phosphorylated H3 antibodies were from Cell Signaling,
a-tubulin antibody was from Sigma, and Eg5 and PARP antibodies were
from Novus Biologicals. Cyclin A and B1 antibodies were from Santa Cruz
Biotechnology; terminal nucleotidyl transferase–mediated nick end labeling
(TUNEL) assay was performed with the APO-Direct apoptosis kit (Phoenix
Flow Systems).
Chromosome spreading. Cells were trypsinized, centrifuged, incubated
in 0.075 mol/L KCl for 10 min at 37jC, and fixed thrice with methanol/
acetic acid (3:1). A drop of this mixture was placed on a microscope slide
and let dry before covering it with antifade containing DAPI.
Western blot and immunoprecipitation. Protein extracts in 1% SDS
were sheared with QIAshredder columns (Qiagen), electrophoresed on 8%
SDS/polyacrylamide gels, and blotted onto a nitrocellulose membrane. All
primary antibodies were incubated overnight, and after incubation with the
peroxidase-conjugated secondary antibody (Pierce), detection was carried
out using the SuperSignal West Pico chemiluminescent substrate (Pierce).
Antibodies used were HDAC4 (Cell Signaling), PARP (Novus Biologicals),
cyclin A and cyclin B1 (Santa Cruz Biotechnology), 53BP1 (Novus
Biologicals), g-H2AX (Upstate), PP2A-A (Upstate), PP2A-C (Upstate),
PP2A-B56 (Sigma), and anti-FLAG (Sigma). HDAC4-FLAG immunoprecip-
itation was carried out as previously described (21).
Results
HDAC4 siRNAs are antiproliferative in tumor cells. Several
HDAC4-specific siRNAs were tested for their ability to inhibit cell
proliferation in a clonogenic assay on HeLa cells. With two
exceptions, all siRNAs produced a z50% decrease in colony
formation with effects comparable to an siRNA directed against the
mitotic kinesin Eg5 (Fig. 1A). Three of the siRNAs were chosen for
further characterization, and transfected into three human tumor
cell lines (HCT-116, HeLa, and A549). Residual HDAC4 protein
expression (Fig. 1B, c) correlated with growth inhibition (Fig. 1B, a)
and inversely correlated with the induction of TUNEL-positive cells
(Fig. 1B, b). No significant effect was observed on the expression of
other HDACs (see below).
To assess the specificity of the antiproliferative effects, we
designed a phenotype-rescue experiment. An HCT-116 clone, stably
expressing HDAC4 devoid of its natural 3¶-untranslated region (UTR),
was generated under the control of a doxycycline-inducible promoter
(HCT-116_HDAC4; Fig. 1C, a) in a cell clone stably expressing the
tetracycline promoter transactivator and suppressor. Subsequently,
siRNAs directed against the 3¶-UTR of the wild-type HDAC4 mRNA
were generated and shown to both decrease endogenous HDAC4 and
lead to proliferation arrest in parental HCT-116 cells as well as in the
HCT-116_HDAC4 cell clone in the absence of doxycycline (Fig. 1C,
black columns in b and c). However, the addition of doxycycline
completely rescued the antiproliferative effect (Fig. 1C, gray columns
in c). qRT-PCR showed efficient silencing of the endogenous but not
of the inducible HDAC4, indicating that antiproliferative effects were
specifically due to HDAC4 knockdown and not to off-target effects
(Fig. 1C, gray columns in b).
Next, we determined gene expression changes induced by
different siRNAs directed against HDAC4 (Supplementary
Fig. S1). RNA was extracted 24 and 32 hours posttransfection of
the siRNAs in HCT-116 cells, and analyzed by microarray. Under
these conditions, a common, high-stringency, target-specific gene
expression signature of 14 and 23 genes at 24 and 32 hours,
respectively, out off18,000 human genes probed on the chip used
(Supplementary Fig. S1; and Materials and Methods) was derived
by hierarchical agglomerative clustering, and revealed the regula-
tion of genes involved in cell-cell interactions, cell shape, apoptosis,
and cell cycle in line with the early phenotypic effects of HDAC4
knockdown (see below). To validate microarray results, we
performed qRT-PCR on a representative subset of these genes
and confirmed the observed change in expression (Supplementary
Fig. S1C). We concluded that HDAC4 knockdown specifically leads
to proliferation defects in human tumor cell lines.
Loss of HDAC4 is well tolerated in normal cells. We next
asked the question about the therapeutic index associated with loss
of HDAC4. The much more tissue-restricted expression pattern of
HDAC4 versus HDAC1 and HDAC3, as representatives of class I,
found in several human tissues argued that its loss may be better
tolerated (Fig. 2A).
Parallel transfection of NHDF and tumor HCT-116 cells with an
HDAC4 siRNA led, in both cell types, to a decrease of f80% in
HDAC4 mRNA (Fig. 2B, b). Whereas no morphologic changes could
be detected in fibroblasts for up to 72 hours posttransfection, HCT-
116 cells lost cell-cell contacts, partly detached, and rounded up, in
line with the changes in the expression levels of several genes
functionally involved in these processes as found by microarray
(Fig. 2B, a) and indicative of cell death.
To assess whether HDAC4 knockdown would cause myelotoxic
effects, we performed an in vitro assay based on colony formation
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of human cord blood myelopoietic progenitors (22, 23) that were
transfected with HDAC4 siRNAs (Fig. 2C). As an internal positive
control, we used an Eg5-siRNA. No significant decrease in colony
formation was produced by any of the HDAC4 siRNAs tested,
whereas Eg5-siRNA gave a significant decrease in colony number.
Expression of HDAC4 and Eg5 was affected to a similar extent
(data not shown).
Growth of normal MEFs from HDAC4 knockout mice is not
affected by HDAC4 loss. To get more insight into the role of
HDAC4 in the cell cycle progression of normal cells, we used MEFs
from HDAC4-knockout (KO) mice. Growth curves of MEFs from
wild-type, HDAC4/+, and HDAC4/ animals were superimpos-
able, indicating that the proliferation of these cells was not impair-
ed even in the complete absence of HDAC4 (Supplementary Fig. S2A).
HDAC4 has a well-documented role in DNA repair in trans-
formed cells by associating with 53BP1 followed by recruitment to
DNA-damage foci (20). HDAC4 depletion in HeLa cells impairs
ionizing radiation–induced DNA-damage repair, leading to cell
death. Gamma-irradiation of wild-type, HDAC4 heterozygous, or
KO MEFs produced a prominent G2-M arrest (Supplementary
Figure 1. HDAC4 knockdown blocks the proliferation of tumor cells. A, colony formation assay of
HDAC4 siRNA–treated HeLa cells; the decrease in colony number correlated with knockdown efficiency.
Eg5-siRNA, positive control of growth inhibition; GL2-siRNA, negative control. B, a, 14C-thymidine
incorporation of tumor cells transfected with HDAC4 siRNAs. b, apoptosis measured after 72 h of
silencing by TUNEL assay. c, HDAC4 knockdown monitored by Western blot of protein extracts at 48 h.
C, a, phenotype rescue of HDAC4 knockdown was obtained in a stable, inducible cell clone stably
expressing HDAC4 cds devoid of its natural 3¶-UTR by using siRNAs mapping in HDAC4 3¶-UTR. In
uninduced conditions (doxycycline), RNAi caused HDAC4 knockdown (b, black columns ) and cell
growth inhibition (c, black columns ), whereas expression of exogenous HDAC4 (+doxycycline) resulted
in no more knockdown of HDAC4 (b, gray columns ) and no proliferation inhibition (c, gray columns ).
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Fig. S2B). However, the kinetics of cell cycle re-entry were identical
for all genotypes, and no increased apoptosis could be observed in
the KO cells, indicating that in these normal cells, DNA-damage
repair could efficiently occur in the complete absence of HDAC4
(Supplementary Fig. S2B and C).
To further investigate the role of HDAC4 in KO cells, we analyzed
the transcriptional profile of wild-type, HDAC4+/, and KO cells
cultured in vitro for two passages after explantation from embryos,
by microarray analysis (see Materials and Methods). As a result, 17
genes were identified to be differentially expressed in at least one
genotype versus the others. Among these, the prm1 gene, encoding
protamine-1, emerged as having the most statistically significant
level of perturbation upon HDAC4 impairment (P < 106). It was
up-regulated in the HDAC4+/ group and even more in the
HDAC4/ group, as compared with the wild-type counterpart,
exhibiting an inverse correlation to HDAC4 expression. This
observation was also confirmed by qRT-PCR analysis (Supplemen-
tary Fig. S2D).
Figure 2. Loss of HDAC4 is well tolerated in normal cells. A, expression levels of HDAC4 in human normal tissues show that HDAC4 has a much more tissue-restricted
expression, specifically, in muscle and testis, as compared with the ubiquitously expressed HDAC1 and HDAC3. B, parallel transfection of HCT-116 cells and
NHDF with HDAC4.13 siRNA led to a cell death phenotype at 72 h posttransfection only in tumor cells, as shown by cell detachment and membrane blebbing (a),
despite similar knockdown efficiencies measured at 24 h (b). C, human myelopoietic progenitors transfected with HDAC4 siRNAs; despite down-regulation of HDAC4
expression, no decrease in clonogenicity was observed. GL2 siRNA served as a negative control, and Eg5 siRNA as a positive control.
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In view of the high expression of HDAC4 in testis where histones
are extensively substituted by protamines during spermiogenesis
(24), this finding suggests that HDAC4 might have a specific role in
this process. We concluded that the biology of HDAC4 is likely to
differ in normal and transformed cells and that HDAC4 depletion
seems to be well tolerated in normal human and murine cells.
Loss of HDAC4 leads to cell cycle arrest and apoptosis in
HeLa cells. We next addressed the mechanism by which HDAC4
depletion leads to proliferation defects in tumor cells. Transfection
of HeLa cells with HDAC4 siRNA led to cell cycle arrest in G2-M 48
hours posttransfection, and to a significant sub-G1 fraction at 72
hours (Fig. 3A, top) with induction of PARP cleavage (Fig. 3B, a).
Addition of a pan-caspase inhibitor prevented the disappearance of
a G2-M peak and the appearance of a sub-G1 fraction, indicating
that HDAC4 depletion leads to caspase-dependent apoptosis
(Fig. 3A, bottom).
HDAC4-interfered cells showed a decreased amount of 53BP1 and
an increased amount of g-H2AX proteins (Fig. 3B, b), in line with
published data (20), and with the notion that inhibition of HDAC4
nuclear translocation inhibits the resolution of g-H2AX foci (25).
We next synchronized HeLa cells either in G1 or in G2 phase
using a double thymidine or a nocodazole blockage, respectively.
Mock or siRNA-transfected cells released from the G1 blockage
could both proceed through S phase, but a substantial fraction of
HDAC4 knockdown cells arrested in G2-M (Fig. 3C, a, left).
Similarly, upon the release of the nocodazole blockage (Fig. 3C,
a, right), a large amount of HDAC4-interfered cells did not further
proceed through the cycle. These data confirmed the observation
that HDAC4 depletion leads to a G2-M blockage in HeLa cells.
In HDAC4-depleted cells, only cyclin B1 and not cyclin A levels
increased as compared with mock-transfected cells, arguing for a
blockage in mitosis rather than in G2 (Fig. 3C, b). This was
confirmed by the immunofluorescence of cells double-stained with
anti–a-tubulin and DAPI, in which we detected a substantial part
of siRNA-transfected cells arrested in mitosis at 48 hours (Fig. 3D,
a). Moreover, analysis of the mitotic index by phosphorylated
H3 staining (Fig. 3D, b, c, d) further supported that HDAC4 RNA
interference (RNAi) caused a blockage of cells in mitosis.
Loss of HDAC4 impairs segregation defects. To investigate
the mechanism of mitotic blockage, we prepared chromosome
spreads from HDAC4 siRNA–transfected HeLa cells. We found that
whereas in control cells f5% to 6% of mitotic cells had separated
chromosomes, in the HDAC4 siRNA–transfected cells up to 52%
of the karyotypes showed abnormal chromatid segregation with
‘‘partial’’ sister chromatid separation occurring in the presence of
unseparated chromosomes; 13% of mitotic cells instead showed
a ‘‘completely separated’’ phenotype (Fig. 4A). This pattern was
found with four different HDAC4-specific siRNAs (data not shown)
and the extent of mitotic anomalies correlated with the HDAC4
knockdown efficiency. Also, infection of HeLa cells with an shRNA-
expressing lentivirus, targeting HDAC4, but not with a control
virus, reduced their growth rate and led to mitotic arrest with
segregation defects (Supplementary Fig. S3A). Segregation defects
upon HDAC4 knockdown were also observed in Saos cells (p53
null) but not in HCT-116 or in A549 cells (p53 positive). Therefore,
we reasoned that perhaps p53 loss might be necessary to observe
segregation defects in cells with HDAC4 loss. To verify this
hypothesis, we transfected HCT-116-E6 cells, harboring the
papilloma E6 protein that blunts p53 expression, with an HDAC4
siRNA. Interestingly, HCT-116-E6 cells presented the same pheno-
type observed in HDAC4-depleted HeLa cells, indicating that
this mitotic defect requires the absence of p53 to be detectable
(Table 1). Moreover, we used A549 cells expressing a lentiviral
vector bearing a p53-specific shRNA. Also in this case, we found
that HDAC4 knockdown led to segregation defects only upon p53
ablation (Supplementary Fig. S3B). None of the p53-defective cell
lines used in this study showed segregation defects in the presence
of HDAC4, suggesting that this mitotic phenotype results from the
simultaneous down-regulation of both gene products.
We recently discovered that HDAC4 associates with PP2A, which
dephosphorylates HDAC4, thus promoting its nuclear import (21,
26). PP2A is a multi-subunit phosphatase and is involved in both
the resolution of DNA repair foci (27) and the protection of
cohesion (28, 29). We therefore asked the question of whether the
impairment of PP2A nuclear import, as a consequence of loss of
HDAC4 expression, might account for some of the phenotypic
effects of HDAC4 siRNAs.
To determine if HDAC4 and PP2A also associate in HeLa cells,
we immunoprecipitated ectopically expressed HDAC4-FLAG and
determined the presence of PP2A subunits in the immunoprecip-
itate. Western blot analysis of anti-FLAG immunoprecipitates
identified PP2A sub-A, PP2A sub-C, and PP2A sub-B56-a (Fig. 4D).
Moreover, the inverse immunoprecipitation of PP2A (subunit C)
confirmed that HDAC4 could be found complexed with PP2A.
We next asked the question of whether PP2A depletion led to
similar mitotic phenotypes as HDAC4 RNAi. Indeed, we found that
silencing of PP2A sub-A led to decreased cell proliferation, G2-M
arrest, increased levels of g-H2AX, followed by PARP cleavage and
apoptosis (Supplementary Fig. S4B).
In order to get insights into a possible link between HDAC4
and PP2A, we further investigated the mitotic phenotype of PP2A
sub-A RNAi in HCT-116 wild type and HCT-116-E6 cells, as well as
in NHDF (Fig. 4B, a and b). RNAi of PP2A sub-A phenocopied
crucial aspects of the mitotic defect pattern observed upon
HDAC4 ablation. Whereas no anomalies could be detected in
PP2A sub-A–deficient NHDF, loss of PP2A sub-A lead to
segregation defects with isolated chromatids and intact chromo-
somes in the same spread (partial phenotype) only in p53-
deficient HCT-116-E6 cells but not in their wild-type counterparts.
In all cases, we made sure that the knockdown efficiencies were
comparable (Supplementary Fig. S4A).
To further dissect the role of PP2A in the mitotic phenotype
observed upon HDAC4 depletion in p53-deficient cells, we
determined the phenotypic consequences of selectively depleting
the PP2A-B56 regulatory subunit, which was specifically found to
be involved in chromatid cohesion (28–30). Indeed, RNAi of PP2A-
B56 in HeLa cells also lead to mitotic arrest and chromatid
segregation defects in f24% of mitotic cells (Fig. 4C).
Despite these striking similarities, we noticed, however, that the
phenotypes resulting from HDAC4 or PP2A ablation also had
distinguishing features. In fact, RNAi of PP2A sub-A led to mitotic
patterns with completely separated chromatids (‘‘separated’’
phenotype) in HCT-116 wild-type cells (Fig. 4B, b) in which RNAi
of HDAC4 never gave mitotic defects. These differences suggest
that the roles of these two proteins only partially overlap.
Discussion
The most important known roles of class IIa HDACs relate to
their involvement in the control of gene expression during
muscle differentiation, regulation of cellular hypertrophy, clonal
cell expansion, or vascular integrity (7, 25, 31–33). HDAC4-KO
mice show pronounced chondrocyte hypertrophy and die of
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Figure 3. Loss of HDAC4 leads to cell cycle arrest and apoptosis of HeLa cells. A, cell cycle of mock or HDAC4 siRNA–transfected cells was analyzed by
fluorescence-activated cell sorting at 24, 48, and 72 h posttransfection in the presence or absence of a pan-caspase inhibitor (percentages of cells in G1, S, G2 phases
as well as the sub-G1 population). B, HDAC4 knockdown induced PARP cleavage (a ) and induction of gH2AX (b; lane 1, mock; lane 2, GL2-siRNA; lane 3,
HDAC4 siRNA). C, a, thymidine blockage in G1 (left ) or a nocodazole blockage in G2-M (right ) were induced 24 h after HDAC4.13 siRNA transfection; 24 h later,
re-entry into the cell cycle was monitored at different time points, showing that HDAC4-interfered cells could not exit a G2-M arrest but could proceed from G1 to G2-M
normally. Bottom histograms, control transfection of HDAC4 siRNA run in parallel, and analyzed 48 h posttransfection. b, Western blot analysis of cyclin A and B1
48 h posttransfection showed an increase in cyclin B1 level in HDAC4 siRNA–transfected cells arguing for an arrest in mitosis. D, a, immunofluorescence of HeLa cells
48 h posttransfection with DAPI and an anti–a-tubulin antibody showed a significant increase of mitotic cells in HDAC4-interfered cells compared with controls
(white arrows ). b, the same sample as in a was stained with DAPI and an anti–phosphorylated H3 histone to determine mitotic index, which was quantified with an
InCell instrument (c ), and confirmed by Western blot analysis (d).
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aberrant ossification (9). In addition to these developmental
functions, HDAC4 has several hallmarks of a tumor suppressor
gene: it was identified as a mediator of p53 and p19ARF-
dependent proliferation arrest and senescence (15), it was found
to be frequently mutated in human cancers (12), and to be
required for the repair of ionizing radiation–induced DNA
damage (20). Intriguingly, activated Ras acts on HDAC4, even
though indirectly, by promoting its nuclear localization (16).
HDAC4 is also a caspase substrate and one of the caspase
cleavage fragments is imported into the nucleus and induces cell
death (18, 19). In addition, we recently identified PP2A, another
well-known tumor suppressor gene, to associate with HDAC4
and to promote its nuclear localization (21, 26). The apparent
tumor suppressor role of HDAC4 is seemingly at odds with our
Figure 4. A, chromosome spreads of HeLa cells 48 h posttransfection with HDAC4 siRNA. The abnormal partial phenotype is characterized by the presence in the
same karyotype of normal X-shaped chromosomes (arrowheads) mixed with free chromatids (arrows ). B, a, chromosome spreads of cells upon PP2A-A RNAi show
representative examples of the partial defect (HCT-116-E6 ) or the ‘‘complete separation’’ defect (HCT-116 wt) or no effect (normal fibroblasts). b, percentages of
chromosome segregation defects in the different cell lines tested (n > 50). C, chromosome spreads of HeLa cells 48 h posttransfection with PP2A-B56 siRNA show
segregation defects. Knockdown efficiency of PP2A-B56 siRNA was determined by qRT-PCR vs. control cells; in these conditions, chromosome defects were observed
in 24% of mitotic cells (n > 50). D, immunoprecipitates of mock-transfected or HDAC4-FLAG–transfected HeLa cells, with an anti-FLAG or anti-PP2A subunit C
antibody, were analyzed by Western blot with the indicated antibodies. Input, 0.01% of whole cell extracts.
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findings of a rather selective requirement for HDAC4 expression
in transformed cells. This latter conclusion is based on
experiments looking at the ablation of HDAC4 expression via
RNAi, making use of siRNAs or shRNAs, or on results obtained
with primary cells from mice with targeted disruptions of the
hdac4 gene. In HeLa cells, loss of HDAC4 resulted in a DNA-
damage response, mitotic arrest, chromatid segregation defects,
and caspase-dependent apoptosis. We note that our data are in
agreement with those reported by Kao and colleagues (20), who
first described the role of HDAC4 in DNA-damage repair. It is
tempting to speculate that at least some of these effects are
mediated by PP2A. In fact, in our hands, loss of either the PP2A
sub-A or PP2A sub-B56 recapitulated the phenotypic features
observed upon HDAC4 RNAi to a significant extent, in line with
some of the known functions of this phosphatase. Indeed, PP2A
is known to be involved in the resolution of DNA-damage foci
by dephosphorylating g-H2AX and, in association with shugoshin,
in the protection of cohesin (28–30). HDAC4 could therefore act
on PP2A trafficking, targeting this phosphatase to both DNA-
damage foci, perhaps via its interaction with 53BP1, and to
cohesin.
The roles of HDAC4 in maintaining genome integrity and in
allowing progression through mitosis are apparently not required
to the same extent in normal cells. This is perhaps best exemplified
by the lack of proliferation defects in HDAC4-KO MEFs, the normal
development of most tissues in the KO animals and the lack of
correlation between HDAC4 expression levels in human tissues and
their proliferative index. Notably, loss of HDAC4 is well tolerated in
human myelopoietic progenitors that readily respond to the
ablation of other genes involved in mitotic progression. Again,
this finding is in line with the lack of hematologic defects in
HDAC4-KO animals. Interestingly, and differently from observa-
tions in HeLa cells, HDAC4-KO MEFs are proficient in ionizing
radiation–induced DNA-damage response, and are indistinguish-
able from their wild-type counterparts (Supplementary Fig. S2).
Our data suggest that HDAC4 is not required for normal
‘‘maintenance’’ cell cycle progression in untransformed cells, in
which it may instead function as a tumor suppressor upon
activation of p53 or other stimuli, thus mediating cell cycle arrest
and exit. In contrast, HDAC4 seems to become indispensable in
transformed cells with a constitutively activated DNA-damage
repair machinery and blunted apoptotic and senescence responses.
Under these conditions, its recruitment to DNA-damage foci, the
stabilization of 53BP1, the association with PP2A, and the resulting
possible effects on DNA-damage foci resolution and cohesin
protection may all contribute to an eventless cell cycle progression
in the presence of replicative stress.
The predominant mechanism(s) by which HDAC4 contributes to
cell cycle progression in transformed cells may differ in a context-
dependent way. Thus, loss of HDAC4 was antiproliferative in both
p53+ and p53 cells, but cohesion defects were noticeable only in
the latter. Interestingly, loss of PP2A sub-A also led to mitotic
segregation defects in p53 wild-type cells, suggesting that the roles
of the two proteins overlap only partially.
Recently, small molecule HDAC inhibitors were described to
affect chromatid cohesion (34–36). In addition, HDAC3 was also
found to be required for centromeric H3K4 deacetylation and sister
chromatid cohesion (37), suggesting a broader role for HDACs
during mitotic progression. It is interesting to note that HDAC3
and HDAC4 may associate and can be found in the same
multiprotein complexes, leading to the question of whether the
phenotypes we have observed in this work may actually involve
additional HDAC subtypes.
Even though not yet understood in detail, the emerging role of
HDAC4 in human malignancies is an attractive one in terms of
therapeutic potentials. A key question is whether deacetylase
activity is involved in the processes described in this article and if
small molecule active site binders are able to recapitulate the RNAi
phenotype. In this respect, a recent publication suggests that the
hydroxamic acid inhibitor LBH589 affects DNA-damage response
and simultaneously influences subcellular localization of HDAC4
(38). This opens the intriguing possibility that HDAC4 inhibition
may contribute to the antitumor activity of the present compounds.
The answer to this question will have to await the availability of
highly selective small molecule inhibitors that could also validate
the hypothesis that selective targeting of this HDAC subtype may
lead to novel compounds with an improved therapeutic index.
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Table 1. Dependence of chromosome segregation
defects on p53 status
Cell line p53 status Chromosome
segregation defects
HeLa Null Yes
SAOS Null Yes
A549 p53+ Wild-type No
A549 p53 Null Yes
HCT-116 Wild-type No
HCT-116-E6 Null Yes
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